Hypersensitive Clinical Trial
Official title:
IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT
The aim of this study is to assess the dermatological and ophthalmological tolerance of the investigational product Baume visage / Face balm RV4942A - RY1985 after 21 days of twice daily use on the study areas, under normal conditions of use. The aim of this study is also to: - evaluate the cutaneous sensitivity by a stinging test at D1 T0 and D22. - evaluate the cutaneous sensitivity by a sensitive scale at D1 T0, D1 Timm*, D8 and D22. - evaluate the soothing efficacy by an efficacy questionnaire at D1 Timm*, D8 and D22. - evaluate the cosmetic acceptability by a questionnaire at D22. This study is conducted as a national, monocentric, non-randomized open trial. The 33 subjects in this study (31 subjects on D22) present hypersensitive, reactive and intolerant skin on face. They are stinger subjects, with a dry to very dry skin. Timm*: 10 to 30 minutes after first application
his study is a national, monocentric, non-randomized open trial, conducted in adults presenting hypersensitive, reactive and intolerant skin on the face, with a dry to very dry skin. The study includes 3 visits, including subjects' selection: - V1: Baseline inclusion - V2: 1 week, intermediate visit - V3: 3 weeks, study end The maximal study duration is 25 days. The evaluation is at 3 times: D1 baseline, D8 at 1 week and D22 at 3 weeks of application of RV4942A - RY1985 with comparison of each time versus baseline. There are twice-daily applications (morning and evening) of the test product on the face. ;